For: | Tanaka A, Uegaki S, Kurihara H, Aida K, Mikami M, Nagashima I, Shiga J, Takikawa H. Hepatic steatosis as a possible risk factor for the development of hepatocellular carcinoma after eradication of hepatitis C virus with antiviral therapy in patients with chronic hepatitis C. World J Gastroenterol 2007; 13(39): 5180-5187 [PMID: 17876888 DOI: 10.3748/wjg.v13.i39.5180] |
---|---|
URL: | https://www.wjgnet.com/1007-9327/full/v13/i39/5180.htm |
Number | Citing Articles |
1 |
Denis Selimovic, Abdelouahid El-Khattouti, Hanan Ghozlan, Youssef Haikel, Ola Abdelkader, Mohamed Hassan. Hepatitis C virus-related hepatocellular carcinoma: An insight into molecular mechanisms and therapeutic strategies. World Journal of Hepatology 2012; 4(12): 342-355 doi: 10.4254/wjh.v4.i12.342
|
2 |
K. Rutter, A. F. Stättermayer, S. Beinhardt, T.-M. Scherzer, P. Steindl-Munda, M. Trauner, P. Ferenci, H. Hofer. Successful anti-viral treatment improves survival of patients with advanced liver disease due to chronic hepatitis C. Alimentary Pharmacology & Therapeutics 2015; 41(6): 521 doi: 10.1111/apt.13085
|
3 |
Toshifumi Tada, Takashi Nishimura, Tomomitsu Matono, Masahiro Yoshida, Minako Yuri, Aoi Fujiwara, Yukihisa Yuri, Tomoyuki Takashima, Nobuhiro Aizawa, Naoto Ikeda, Hirayuki Enomoto, Takashi Kumada, Hiroko Iijima. Association of liver stiffness and steatosis with hepatocellular carcinoma development in patients with hepatitis C virus infection who received direct‐acting antiviral therapy and achieved sustained virological response. Hepatology Research 2021; 51(8): 860 doi: 10.1111/hepr.13677
|
4 |
Luca Valenti, MariaGrazia Rumi, Enrico Galmozzi, Alessio Aghemo, Benedetta Del Menico, Stella De Nicola, Paola Dongiovanni, Marco Maggioni, Anna Ludovica Fracanzani, Raffaela Rametta, Massimo Colombo, Silvia Fargion. Patatin-Like Phospholipase Domain-Containing 3 I148M Polymorphism, Steatosis, and Liver Damage in Chronic Hepatitis C σ. Hepatology 2011; 53(3): 791 doi: 10.1002/hep.24123
|
5 |
Akio Miyasaka, Yuichi Yoshida, Akiko Suzuki, Kei Sawara, Yasuhiro Takikawa. A Novel Standard for Hepatocellular Carcinoma Screening Intensity After Hepatitis C Elimination. International Journal of General Medicine 2021; : 8935 doi: 10.2147/IJGM.S344492
|
6 |
Jacob Alexander, Michael Torbenson, Tsung‐Teh Wu, Matthew M. Yeh. Non‐alcoholic fatty liver disease contributes to hepatocarcinogenesis in non‐cirrhotic liver: A clinical and pathological study. Journal of Gastroenterology and Hepatology 2013; 28(5): 848 doi: 10.1111/jgh.12116
|
7 |
Luigi Adinolfi, Luca Rinaldi, Barbara Guerrera, Luciano Restivo, Aldo Marrone, Mauro Giordano, Rosa Zampino. NAFLD and NASH in HCV Infection: Prevalence and Significance in Hepatic and Extrahepatic Manifestations. International Journal of Molecular Sciences 2016; 17(6): 803 doi: 10.3390/ijms17060803
|
8 |
José Velosa, Fátima Serejo, Rui Marinho, Joana Nunes, Helena Glória. Eradication of Hepatitis C Virus Reduces the Risk of Hepatocellular Carcinoma in Patients with Compensated Cirrhosis. Digestive Diseases and Sciences 2011; 56(6): 1853 doi: 10.1007/s10620-011-1621-2
|
9 |
Phumelele Yvonne Siphepho, Yi-Ting Liu, Ciniso Sylvester Shabangu, Jee-Fu Huang, Chung-Feng Huang, Ming-Lun Yeh, Ming-Lung Yu, Shu-Chi Wang. The Impact of Steatosis on Chronic Hepatitis C Progression and Response to Antiviral Treatments. Biomedicines 2021; 9(10): 1491 doi: 10.3390/biomedicines9101491
|
10 |
Naoki Kawagishi, Goki Suda, Akinobu Nakamura, Megumi Kimura, Osamu Maehara, Kazuharu Suzuki, Akihisa Nakamura, Masatsugu Ohara, Takaaki Izumi, Machiko Umemura, Masato Nakai, Takuya Sho, Mitsuteru Natsuizaka, Kenichi Morikawa, Koji Ogawa, Yusuke Kudo, Mutsumi Nishida, Hideaki Miyoshi, Naoya Sakamoto, Umberto Vespasiani-Gentilucci. Liver steatosis and dyslipidemia after HCV eradication by direct acting antiviral agents are synergistic risks of atherosclerosis. PLOS ONE 2018; 13(12): e0209615 doi: 10.1371/journal.pone.0209615
|
11 |
Ning Geng, Yong-Ning Xin, Harry Hua-Xiang Xia, Man Jiang, Jian Wang, Yang Liu, Li-Zhen Chen, Shi-Ying Xuan. Association of PNPLA3 I148M Variant With Chronic Viral Hepatitis, Autoimmune Liver Diseases and Outcomes of Liver Transplantation. Hepatitis Monthly 2015; 15(4) doi: 10.5812/hepatmon.15(4)2015.26459
|
12 |
Sumio Watanabe, Nobuyuki Enomoto, Kazuhiko Koike, Namiki Izumi, Hajime Takikawa, Etsuko Hashimoto, Fuminori Moriyasu, Hiromitsu Kumada, Michio Imawari. Cancer preventive effect of pegylated interferon α‐2b plus ribavirin in a real‐life clinical setting in Japan: PERFECT interim analysis. Hepatology Research 2011; 41(10): 955 doi: 10.1111/j.1872-034X.2011.00847.x
|
13 |
Lilach Goldberg-Bittman, Aliza Amiel, Ruth Hadary, Moshe D. Fejgin, Miriam Quitt, Yona Kitay-Cohen. Telomere capture in hepatitis C infection. Cancer Genetics and Cytogenetics 2009; 191(2): 63 doi: 10.1016/j.cancergencyto.2009.01.013
|
14 |
Kazumichi Abe, Hiroto Wakabayashi, Haruo Nakayama, Tomohiro Suzuki, Masahito Kuroda, Naoe Yoshida, Jun Tojo, Atsuko Kogure, Tsuyoshi Rai, Hironobu Saito, Shinji Mukai, Masashi Fujita, Manabu Hayashi, Atsushi Takahashi, Hiromasa Ohira, Ming-Lung Yu. Factors associated with hepatocellular carcinoma occurrence after HCV eradication in patients without cirrhosis or with compensated cirrhosis. PLOS ONE 2020; 15(12): e0243473 doi: 10.1371/journal.pone.0243473
|
15 |
Sheetal Trivedi, Satyapramod Murthy, Himanshu Sharma, Alex S. Hartlage, Arvind Kumar, Sashi V. Gadi, Peter Simmonds, Lokendra V. Chauhan, Troels K.H. Scheel, Eva Billerbeck, Peter D. Burbelo, Charles M. Rice, W. Ian Lipkin, Kurt Vandegrift, John M. Cullen, Amit Kapoor. Viral persistence, liver disease, and host response in a hepatitis C–like virus rat model. Hepatology 2018; 68(2): 435 doi: 10.1002/hep.29494
|
16 |
Ai-Guo Wang, Hyung-Bae Moon, Jung-Il Chae, Jin-Man Kim, Ye-Eun Kim, Dae-Yeul Yu, Dong-Seok Lee. Steatosis induced by the accumulation of apolipoprotein A-I and elevated ROS levels in H-ras12V transgenic mice contributes to hepatic lesions. Biochemical and Biophysical Research Communications 2011; 409(3): 532 doi: 10.1016/j.bbrc.2011.05.039
|
17 |
Gregory A. Michelotti, Mariana V. Machado, Anna Mae Diehl. NAFLD, NASH and liver cancer. Nature Reviews Gastroenterology & Hepatology 2013; 10(11): 656 doi: 10.1038/nrgastro.2013.183
|
18 |
Amiel A., Fejgin M. D., Goldberg-Bittman L., Sharoni R., Hadary R., Kitay-Cohen Y.. Telomere Aggregates in Hepatitis C Patients. Cancer Investigation 2009; 27(6): 650 doi: 10.1080/07357900802350806
|
19 |
Mariana V. Machado, Helena Cortez-Pinto. Insulin resistance and steatosis in chronic hepatitis C. Annals of Hepatology 2009; 8: S67 doi: 10.1016/S1665-2681(19)31829-0
|
20 |
Eleni Koukoulioti, Thomas Berg. Evidence‐based Gastroenterology and Hepatology 4e. 2019; : 470 doi: 10.1002/9781119211419.ch32
|
21 |
A. Martini, G. Fattovich, M. Guido, E. Bugianesi, A. Biasiolo, D. Ieluzzi, A. Gallotta, G. Fassina, C. Merkel, A. Gatta, F. Negro, P. Pontisso. HCV genotype 3 and squamous cell carcinoma antigen (SCCA)‐IgM are independently associated with histological features of NASH in HCV‐infected patients. Journal of Viral Hepatitis 2015; 22(10): 800 doi: 10.1111/jvh.12394
|
22 |
Ali Shojaeian, Mohsen Nakhaie, Zahra Sobhi Amjad, Armin Khaghani Boroujeni, Somayeh Shokri, Shahab Mahmoudvand. Leveraging metformin to combat hepatocellular carcinoma: its therapeutic promise against hepatitis viral infections. Journal of Cancer Metastasis and Treatment 2024; doi: 10.20517/2394-4722.2023.147
|
23 |
Norberto C. Chávez-Tapia, Nahum Méndez-Sánchez, Misael Uribe. Role of nonalcoholic fatty liver disease in hepatocellular carcinoma. Annals of Hepatology 2009; 8: S34 doi: 10.1016/S1665-2681(19)31824-1
|
24 |
Shinn‐Jang Hwang, Shou‐Dong Lee. Hepatic steatosis and hepatitis C: Still unhappy bedfellows?. Journal of Gastroenterology and Hepatology 2011; 26(s1): 96 doi: 10.1111/j.1440-1746.2010.06542.x
|
25 |
Paola Dongiovanni, Stefano Romeo, Luca Valenti. Hepatocellular carcinoma in nonalcoholic fatty liver: Role of environmental and genetic factors. World Journal of Gastroenterology 2014; 20(36): 12945-12955 doi: 10.3748/wjg.v20.i36.12945
|
26 |
Vicência M.R. de Lima, Claudia P.M.S. Oliveira, Venancio A.F. Alves, Maria Cristina Chammas, Ellen Pierre Oliveira, José Tadeu Stefano, Evandro Sobroza de Mello, Giovanni Guido Cerri, Flair José Carrilho, Stephen H. Caldwell. A rodent model of NASH with cirrhosis, oval cell proliferation and hepatocellular carcinoma. Journal of Hepatology 2008; 49(6): 1055 doi: 10.1016/j.jhep.2008.07.024
|
27 |
Naoki Hiramatsu, Tsugiko Oze, Tetsuo Takehara. Suppression of hepatocellular carcinoma development in hepatitis C patients given interferon‐based antiviral therapy. Hepatology Research 2015; 45(2): 152 doi: 10.1111/hepr.12393
|
28 |
Nobuyoshi Fukushima, Ryoko Kuromatsu, Teruko Arinaga‐Hino, Eiji Ando, Akio Takata, Shuji Sumie, Masahito Nakano, Takumi Kawaguchi, Tatsuya Ide, Takuji Torimura, Michio Sata. Adipocytokine involvement in hepatocellular carcinoma after sustained response to interferon for chronic hepatitis C. Hepatology Research 2010; 40(9): 911 doi: 10.1111/j.1872-034X.2010.00699.x
|
29 |
Divya Ramnath, Katharine M. Irvine, Samuel W. Lukowski, Leigh U. Horsfall, Zhixuan Loh, Andrew D. Clouston, Preya J. Patel, Kevin J. Fagan, Abishek Iyer, Guy Lampe, Jennifer L. Stow, Kate Schroder, David P. Fairlie, Joseph E. Powell, Elizabeth E. Powell, Matthew J. Sweet. Hepatic expression profiling identifies steatosis-independent and steatosis-driven advanced fibrosis genes. JCI Insight 2018; 3(14) doi: 10.1172/jci.insight.120274
|
30 |
K. R. Dudina, P. A. Belyy, I. V. Maev, N. Kh. Safiullina, E. A. Klimova, S. A. Shutko, O. O. Znoyko, N. D. Yushchuk. Long-Term Monitoring of Liver Fibrosis and Steatosis in Patients with Chronic Hepatitis C after Achieving a Sustained Virologic Response to Antiviral Therapy. Russian Journal of Gastroenterology, Hepatology, Coloproctology 2023; 32(5): 31 doi: 10.22416/1382-4376-2022-32-5-31-42
|
31 |
Hideo Kunimoto, Kenji Ikeda, Yushi Sorin, Shunichiro Fujiyama, Yusuke Kawamura, Masahiro Kobayashi, Hitomi Sezaki, Tetsuya Hosaka, Norio Akuta, Satoshi Saitoh, Fumitaka Suzuki, Yoshiyuki Suzuki, Yasuji Arase, Hiromitsu Kumada. Long-Term Outcomes of Hepatitis-C-Infected Patients Achieving a Sustained Virological Response and Undergoing Radical Treatment for Hepatocellular Carcinoma. Oncology 2016; 90(3): 167 doi: 10.1159/000443891
|
32 |
Current World Literature. Current Opinion in Lipidology 2008; 19(6): 600 doi: 10.1097/MOL.0b013e32831b7581
|
33 |
Anahita Sadeghi, Roya Amiri, Elham Akbarpour, Babak Mirminachi, Amir‐Houshang Sharifi, Shahin Merat. Changes in liver fibrosis in patients with chronic hepatitis C after successful direct‐acting antiviral therapy. International Journal of Clinical Practice 2021; 75(6) doi: 10.1111/ijcp.14145
|
34 |
Toshifumi Tada, Takashi Kumada, Tomomitsu Matono, Shinichiro Nakamura, Masahiko Sue, Yu Matsuo, Masahiro Takatani, Hiroko Iijima, Junko Tanaka. Characteristics of hepatocellular carcinoma in patients with hepatitis C virus who received direct‐acting antiviral therapy and achieved sustained virological response: The impact of a hepatologist on surveillance. JGH Open 2022; 6(7): 462 doi: 10.1002/jgh3.12774
|
35 |
Ryu Sasaki, Kazumi Yamasaki, Seigo Abiru, Atsumasa Komori, Shinya Nagaoka, Akira Saeki, Satoru Hashimoto, Shigemune Bekki, Yuki Kugiyama, Atsushi Kuno, Masaaki Korenaga, Akira Togayachi, Makoto Ocho, Masashi Mizokami, Hisashi Narimatsu, Tatsuki Ichikawa, Kazuhiko Nakao, Hiroshi Yatsuhashi, Ming-Lung Yu. Serum Wisteria Floribunda Agglutinin-Positive Mac-2 Binding Protein Values Predict the Development of Hepatocellular Carcinoma among Patients with Chronic Hepatitis C after Sustained Virological Response. PLOS ONE 2015; 10(6): e0129053 doi: 10.1371/journal.pone.0129053
|
36 |
Lindsay Matthews, David E. Kleiner, Cheryl Chairez, Maryellen McManus, Mary Jane Nettles, Kira Zemanick, Caryn Gee Morse, Debra Benator, Joseph A. Kovacs, Colleen Hadigan. Pioglitazone for Hepatic Steatosis in HIV/Hepatitis C Virus Coinfection. AIDS Research and Human Retroviruses 2015; 31(10): 961 doi: 10.1089/aid.2015.0093
|
37 |
Roberta D'Ambrosio, Massimo Colombo. Should surveillance for liver cancer be modified in hepatitis C patients after treatment‐related cirrhosis regression?. Liver International 2016; 36(6): 783 doi: 10.1111/liv.13106
|
38 |
Manuel Romero-Gómez. Pathogenesis and natural course of hepatic steatosis and insulin resistance in patients with hepatitis C. Current Hepatitis Reports 2008; 7(3): 113 doi: 10.1007/s11901-008-0024-0
|
39 |
Roberta D'Ambrosio, Cristina Della Corte, Massimo Colombo. Hepatocellular Carcinoma in Patients with a Sustained Response to Anti-Hepatitis C Therapy. International Journal of Molecular Sciences 2015; 16(8): 19698 doi: 10.3390/ijms160819698
|
40 |
Hisamitsu Miyaaki, Tatsuki Ichikawa, Naota Taura, Satoshi Miuma, Hidetaka Shibata, Hajime Isomoto, Fuminao Takeshima, Kazuhiko Nakao. Predictive Value of the Fibrosis Scores in Patients with Chronic Hepatitis C Associated with Liver Fibrosis and Metabolic Syndrome. Internal Medicine 2011; 50(11): 1137 doi: 10.2169/internalmedicine.50.4447
|
41 |
Andrew Aronsohn, Donald Jensen. HCV Eradication: Implications for Disease Resolution. Current Hepatitis Reports 2011; 10(1): 27 doi: 10.1007/s11901-010-0076-9
|
42 |
Takao Watanabe, Yoshio Tokumoto, Kouji Joko, Kojiro Michitaka, Norio Horiike, Yoshinori Tanaka, Fujimasa Tada, Yoshiyasu Kisaka, Seiji Nakanishi, Kazuhiko Yamauchi, Atsushi Yukimoto, Masashi Hirooka, Masanori Abe, Yoichi Hiasa. Predictors of hepatocellular carcinoma occurrence after direct‐acting antiviral therapy in patients with hepatitis C virus infection. Hepatology Research 2019; 49(2): 136 doi: 10.1111/hepr.13278
|
43 |
Andrew Aronsohn, Nancy Reau. Long-term Outcomes After Treatment With Interferon and Ribavirin in HCV Patients. Journal of Clinical Gastroenterology 2009; 43(7): 661 doi: 10.1097/MCG.0b013e31819f66e2
|
44 |
Youngmin A. Lee, Scott L. Friedman. Reversal, maintenance or progression: What happens to the liver after a virologic cure of hepatitis C?. Antiviral Research 2014; 107: 23 doi: 10.1016/j.antiviral.2014.03.012
|
45 |
Ira M. Jacobson, Joseph K. Lim, Michael W. Fried. American Gastroenterological Association Institute Clinical Practice Update—Expert Review: Care of Patients Who Have Achieved a Sustained Virologic Response After Antiviral Therapy for Chronic Hepatitis C Infection. Gastroenterology 2017; 152(6): 1578 doi: 10.1053/j.gastro.2017.03.018
|
46 |
Ziv Ben Ari, Ella Weitzman, Michal Safran. Oncogenic Viruses and Hepatocellular Carcinoma. Clinics in Liver Disease 2015; 19(2): 341 doi: 10.1016/j.cld.2015.01.006
|
47 |
Y. Kitay-Cohen, L. Goldberg-Bittman, R. Hadary, M.D. Fejgin, A. Amiel. Telomere length in Hepatitis C. Cancer Genetics and Cytogenetics 2008; 187(1): 34 doi: 10.1016/j.cancergencyto.2008.08.006
|
48 |
Lan Liu, Yanxin Huang, Kaili Zhang, Shupeng Song, Shuangxing Li, Yongguo Li, Yinghua Lan. Hepatitis B core antigen regulates dendritic cell proliferation and apoptosis through regulation of PKC/NF‑κB signaling pathway. Molecular Medicine Reports 2018; doi: 10.3892/mmr.2018.9604
|
49 |
Seng Gee Lim, Alessio Aghemo, Pei-Jer Chen, Yock Young Dan, Edward Gane, Rino Gani, Robert G Gish, Richard Guan, Ji Dong Jia, Kieron Lim, Teerha Piratvisuth, Samir Shah, Mitchell L Shiffman, Frank Tacke, Soek Siam Tan, Tawesak Tanwandee, Khin Maung Win, Cihan Yurdaydin. Management of hepatitis C virus infection in the Asia-Pacific region: an update. The Lancet Gastroenterology & Hepatology 2017; 2(1): 52 doi: 10.1016/S2468-1253(16)30080-2
|
50 |
Takumi Kawaguchi, Hironori Koga, Takuji Torimura. Recent Advances in the Pathogenesis of Hepatitis C Virus-Related Non-Alcoholic Fatty Liver Disease and Its Impact on Patients Cured of Hepatitis C. Current Hepatology Reports 2017; 16(4): 317 doi: 10.1007/s11901-017-0370-x
|
51 |
Christine C Hsu, Harish Gopalakrishna, Maria Mironova, Mei-Hsuan Lee, Chien-Jen Chen, Hwai-I Yang, Manfred Wiese, Kyong-Mi Chang, Elizabeth C Wright, Tomilowo Abijo, Jordan J Feld, David E Kaplan. Risk of Hepatocellular Carcinoma After Spontaneous Clearance of Hepatitis C Virus and in Noncirrhosis Chronic Hepatitis C Patients With Sustained Virological Response: A Systematic Review. Clinical Infectious Diseases 2023; 77(Supplement_3): S245 doi: 10.1093/cid/ciad380
|
52 |
Norah A. Terrault, Tarek I. Hassanein. Management of the patient with SVR. Journal of Hepatology 2016; 65(1): S120 doi: 10.1016/j.jhep.2016.08.001
|
53 |
Hwajeong Lee, Sanaz Ainechi, Karen Dresser, Elizabeth M. Kurian. Central Portalization Correlates with Fibrosis but Not with Risk Factors for Nonalcoholic Steatohepatitis in Steatotic Chronic Hepatitis C. International Journal of Hepatology 2014; 2014: 1 doi: 10.1155/2014/329297
|
54 |
Muhammad Y. Sheikh. Steatosis in hepatitis C: Mechanisms and basic concepts. Current Hepatitis Reports 2008; 7(4): 152 doi: 10.1007/s11901-008-0030-2
|
55 |
Magnus Hedenstierna, Ali Nangarhari, Ola Weiland, Soo Aleman. Diabetes and Cirrhosis Are Risk Factors for Hepatocellular Carcinoma After Successful Treatment of Chronic Hepatitis C. Clinical Infectious Diseases 2016; 63(6): 723 doi: 10.1093/cid/ciw362
|
56 |
Thierry Poynard, Nezam H Afdhal. Perspectives on Fibrosis Progression in Hepatitis C: An à la Carte Approach to Risk Factors and Staging of Fibrosis. Antiviral Therapy 2010; 15(3): 281 doi: 10.3851/IMP1535
|
57 |
Kosuke Matsumoto, Hisamitsu Miyaaki, Masanori Fukushima, Ryu Sasaki, Masafumi Haraguchi, Satoshi Miuma, Kazuhiko Nakao. The impact of single‑nucleotide polymorphisms on liver stiffness and controlled attenuation parameter in patients treated with direct‑acting antiviral drugs for hepatitis C infection. Biomedical Reports 2021; 16(2) doi: 10.3892/br.2021.1492
|
58 |
Yasuhiro Asahina. JSH Guidelines for the Management of Hepatitis C Virus Infection, 2019 Update; Protective Effect of Antiviral Therapy against Hepatocarcinogenesis. Hepatology Research 2020; 50(7): 775 doi: 10.1111/hepr.13501
|
59 |
Hiroji Shinkawa, Shogo Tanaka, Shigekazu Takemura, Tokuji Ito, Takanori Aota, Masaki Koda, Toru Miyazaki, Takatsugu Yamamoto, Shoji Kubo. Obesity and recurrence‐free survival in patients with hepatocellular carcinoma after achieving sustained virological response to interferon therapy for chronic hepatitis C. Annals of Gastroenterological Surgery 2018; 2(4): 319 doi: 10.1002/ags3.12183
|
60 |
P. Loria, L.E. Adinolfi, S. Bellentani, E. Bugianesi, A. Grieco, S. Fargion, A. Gasbarrini, C. Loguercio, A. Lonardo, G. Marchesini, F. Marra, M. Persico, D. Prati, G. Svegliati- Baroni. Practice guidelines for the diagnosis and management of nonalcoholic fatty liver disease. Digestive and Liver Disease 2010; 42(4): 272 doi: 10.1016/j.dld.2010.01.021
|
61 |
Akira Sato, Michio Sata, Kenji Ikeda, Takashi Kumada, Namiki Izumi, Yasuhiro Asahina, Yukio Osaki, Kazuaki Chayama, Shuichi Kaneko, Akito Sakai, Morikazu Onji, Yoichi Hiasa, Takumi Omura, Itaru Ozeki, Osamu Yokosuka, Shuichiro Shiina, Mariko Itsubo, Shuhei Nishiguchi, Katsuharu Hirano, Tatsuya Ide, Shotaro Sakisaka, Takahiro Yamasaki, Isao Hidaka, Masatoshi Tanaka, Soo Ryang Kim, Takafumi Ichida. Clinical Characteristics of Patients who Developed Hepatocellular Carcinoma after Hepatitis C Virus Eradication with Interferon Therapy: Current Status in Japan. Internal Medicine 2013; 52(24): 2701 doi: 10.2169/internalmedicine.52.1180
|
62 |
Srikanta Dash, Yucel Aydin, Tong Wu. Integrated stress response in hepatitis C promotes Nrf2-related chaperone-mediated autophagy: A novel mechanism for host-microbe survival and HCC development in liver cirrhosis. Seminars in Cell & Developmental Biology 2020; 101: 20 doi: 10.1016/j.semcdb.2019.07.015
|
63 |
Masato Nakai, Yoshiya Yamamoto, Masaru Baba, Goki Suda, Akinori Kubo, Yoshimasa Tokuchi, Takashi Kitagataya, Ren Yamada, Taku Shigesawa, Kazuharu Suzuki, Akihisa Nakamura, Takuya Sho, Kenichi Morikawa, Koji Ogawa, Ken Furuya, Naoya Sakamoto. Prediction of hepatocellular carcinoma using age and liver stiffness on transient elastography after hepatitis C virus eradication. Scientific Reports 2022; 12(1) doi: 10.1038/s41598-022-05492-5
|